Sai Parenterals' Australian unit, Noumed, renewed a 3-year supply agreement valued at AUD 30 million (approx. INR 204 Cr). This expands the group's total Australian OTC contracted supply to AUD 232 million.
Sai Parenteral's Limited has fixed the record date for its 25th AGM, ensuring eligible shareholders can vote electronically on upcoming resolutions.
Sai Parenterals to acquire stakes in two pharma assets, Saicriti Pharma and Prathyak Laboratories, for Rs. 83.83 Cr and Rs. 18.02 Cr respectively, utilizing IPO proceeds for strategic expansion.
Sai Parenterals' Australian subsidiary renewed an exclusive OTC supply agreement for 7½ years, valued at AUD 202 million (approx. INR 1300 Cr). This extends their partnership with leading pharmacy networks.
Sai Parenterals reports strong FY26 results with revenue up 140.37% and PAT up 45.52%, driven by CDMO exports and Australian subsidiary integration. Capex of ~₹440 crore for expansion is ongoing.
